Powered by: Motilal Oswal

News

Neutral Divi`s Laboratories For Target Rs.5,630 By Motilal Oswal Financial Services Ltd Custom synthesis outperforms; generics vertical underperforms Augmenting capabilities/capacities in Peptides/contrast media space * Divi’s Labs (DIVI) delivered better-than-expected financial performance in 2QFY25. The custom synthesis (CS) segment has maintained its strong YoY growth momentum for four quarters now. DIVI continues to face pricing challenges in its generics segment. * Capex programs (Unit 3/Kakinada) remain on track and will cater to future requirement...
Neutral Divi`s Laboratories For Target Rs.5,630 By Motilal Oswal Financial Services Ltd
Neutral Divi`s Laboratories For Target Rs.5,630 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services ltd
2024-11-30 10:28:18 am
Buy Divi`s Labs Limited For Target Rs.6,983 By Choice Broking Ltd Divis Laboratories reported robust quarterly numbers which were above estimations. Revenue at INR 23,380mn was up 22.5% YoY and 10.4% QoQ, driven by growth in the Custom Synthesis business, which saw an increased demand from current and potential customers. The constant currency growth stood at 21%. EBITDA saw robust growth of 49.5% YoY and 15.1% QoQ to INR 7,160mn, with an EBITDA margin of 30.6%, expanding 553bps YoY and 126bps QoQ due to stability in the material costs. The product mix...
Buy Divi`s Labs Limited For Target Rs.6,983 By Choice Broking Ltd
Buy Divi`s Labs Limited For Target Rs.6,983 By Choice Broking Ltd
Source: Choice Broking Ltd
2024-11-24 11:51:46 am
Stock Picks : Federal Bank Ltd and Divi`s Laboratories Ltd By ICICI Direct Federal Bank Ltd Buy Federal Bank Ltd @ 210.50-211.00 Target 213.00 Stop Loss 209.40   Divi’s Laboratories Ltd Buy Divi’s Laboratories Ltd @ 5975-5979 Target 6039.00 Stop Loss 5947.40   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : Federal Bank Ltd and Divi`s Laboratories Ltd By ICICI Direct
Stock Picks : Federal Bank Ltd and Divi`s Laboratories Ltd By ICICI Direct
Source: ICICI Direct
2024-11-22 10:37:55 am
Stock Picks : Mahindra&Mahindra Ltd and Divi`s Laboratories Ltd By ICICI Direct Mahindra&Mahindra Ltd Buy Mahindra&Mahindra Ltd @ 2836-2840 Target 2869.00 Stop Loss 2821.40   Divi’s Laboratories Ltd Buy Divi’s Laboratories Ltd @ 5878-5882 Target 5942.00 Stop Loss 2821.40   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : Mahindra&Mahindra Ltd and Divi`s Laboratories Ltd By ICICI Direct
Stock Picks : Mahindra&Mahindra Ltd and Divi`s Laboratories Ltd By ICICI Direct
Source: ICICI Direct
2024-11-21 09:40:39 am
Diwali Technical Pick 2024 : Buy Divis Laboratory Ltd For Target Rs. 5140 - Nirmal Bang Ltd Divis Laboratory Ltd * The Stock has given breakout of a Rounding formation on the longer term charts. * The stock has given three year Breakout with increase in volumes post breakout. Positive RSI Crossover is seen on the weekly charts. * Stock is well placed above all the important moving averages. * Therefore, investor can buy the stock at 5720 and on dips to Rs 5470 for a target of Rs 7200 with a strict stop loss placed below Rs 5140   Buy Divis Laboratory ...
Diwali Technical Pick 2024 : Buy Divis Laboratory Ltd For Target Rs. 5140 - Nirmal Bang Ltd
Diwali Technical Pick 2024 : Buy Divis Laboratory Ltd For Target Rs. 5140 - Nirmal Bang Ltd
Source: Nirmal Bang Ltd
2024-10-24 12:32:13 pm
Stock Picks : GAIL India Ltd And Divis Laboratories Ltd By ICICI Direct GAIL India Ltd Buy GAIL India Ltd @ 230-231 Target 233.50 Stop Loss 229.40   Divis Laboratories Ltd  Buy Divis Laboratories Ltd  @ 4870-4875 Target 4926.00 Stop Loss 4846.00   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : GAIL India Ltd And Divis Laboratories Ltd By ICICI Direct
Stock Picks : GAIL India Ltd And Divis Laboratories Ltd By ICICI Direct
Source: ICICI Direct
2024-08-13 10:36:02 am
Buy Divi`s Laboratories Ltd For Target Rs.5,000 By Choice Broking Ltd Divis Laboratories reported quarterly numbers below estimations. Revenue at INR 21,180 million was up 19.1% YoY and down 8.0% QoQ, driven by a decline in the Custom Synthesis business. The constant currency growth stood at 18%. EBITDA saw robust growth of 23.4% YoY but declined 14.9% QoQ to INR 6,220 million, with an EBITDA margin of 29.4%, expanding 102 bps YoY but declining 237 bps QoQ due to increased material costs. The product mix for generics to custom synthesis was reported at 51% and ...
Buy Divi`s Laboratories Ltd For Target Rs.5,000 By Choice Broking Ltd
Buy Divi`s Laboratories Ltd For Target Rs.5,000 By Choice Broking Ltd
Source: Choice Broking
2024-08-10 11:17:58 am
Neutral Divi`s Laboratories Ltd For Target Rs. 4,680 By Motilal Oswal Financial Services Custom Synthesis outperforms; API underperforms Work-in-progress to improve prospects in peptide/contrast media space * DIVI delivered a miss on 1QFY25 earnings performance, due to the ongoing pricing headwinds in API segment and muted Nutraceutical sales. The custom synthesis (CS) segment maintained strong growth momentum for this quarter as well. * We largely maintain our estimates for FY25/FY26. We value DIVI at 43x 12M forward earnings to arrive at a TP of INR4,680. * DIVI con...
Neutral Divi`s Laboratories Ltd For Target Rs. 4,680 By Motilal Oswal Financial Services
Neutral Divi`s Laboratories Ltd For Target Rs. 4,680 By Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
2024-08-07 03:40:25 pm
Divi's Laboratories declines despite reporting 21% rise in consolidated net profit in Q1 Divi's Laboratories is currently trading at Rs. 4831.00, down by 159.35 points or 3.19% from its previous closing of Rs. 4990.35 on the BSE. The scrip opened at Rs. 4987.95 and has touched a high and low of Rs. 4987.95 and Rs. 4777.30 respectively. So far 12756 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 5011.00 on 02-Aug-2024 and a 52 week low of Rs. 3300.00 on 06-Nov-2023. Last one week high and low of...
Divi's Laboratories declines despite reporting 21% rise in consolidated net profit in Q1
Divi's Laboratories declines despite reporting 21% rise in consolidated net profit in Q1
Source: Accord Fintech
2024-08-05 12:18:43 pm
Divi`s Labs Q4 net profit jumps over 67 pc, declares dividend of Rs 30 per share Pharma major Divi’s Laboratories Ltd on Saturday reported a 67.6 per cent jump in its consolidated net profit to Rs 538 crore for the Jan-March quarter of 203-24 compared to the corresponding figure of Rs 321 crore in the same period last year.  Revenue for the quarter grew 18 per cent to Rs 2,303 crore from Rs 1,951 crore in the same period a year ago. The company’s board has recommended a final dividend of Rs 30 per equity share of face value of Rs 2 each for the fina...
Divi`s Labs Q4 net profit jumps over 67 pc, declares dividend of Rs 30 per share
Divi`s Labs Q4 net profit jumps over 67 pc, declares dividend of Rs 30 per share
Source: IANS
2024-05-26 08:56:01 am
Sensex falls more than 800 points, L&T drags Nifty   Sensex and Nifty extended their morning session losses. Till 1:30 PM, the majority of the Indices were red as Sensex was down 802 points or 1.05 per cent at 72,664 points while Nifty was down 261 points or 1.17 per cent at 22,041 points. Pressure was observed from the midcap and smallcap indices. The Nifty Small Cap 100 index was down 318 points, or 1.94 per cent at 16,142 points, and the Nifty Midcap was down 592 points, or 1.18 per cent, at 49,444 points. The rise in India V...
Sensex falls more than 800 points, L&T drags Nifty
Sensex falls more than 800 points, L&T drags Nifty
Source: IANS
2024-05-09 02:46:54 pm
Divi's Laboratories surges on planning for capacity addition at manufacturing facility Divi's Laboratories is currently trading at Rs. 3988.50, up by 147.75 points or 3.85% from its previous closing of Rs. 3840.75 on the BSE. The scrip opened at Rs. 3855.00 and has touched a high and low of Rs. 4018.00 and Rs. 3840.75 respectively. So far 17087 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 4072.35 on 04-Jan-2024 and a 52 week low of Rs. 3050.15 on 22-May-2023. Last one week high and low of t...
Divi's Laboratories surges on planning for capacity addition at manufacturing facility
Divi's Laboratories surges on planning for capacity addition at manufacturing facility
Source: Accord Fintech
2024-04-26 12:01:03 pm
Sell Divi's Laboratories Ltd. For Target Rs. 3017 By Elara Securities India Divi’s Laboratories’ (DIVI IN) Q3FY24 revenue and EBITDA missed our estimates by 13% and 28%, respectively. Revenue grew just 8.6% YoY. EBITDA margin improved 250bps YoY and 130bps QoQ, but was still a far cry from the historic 34%+ levels, recovery to which the stock is pricing in, in our view. No visibility of a major step-up in earnings DIVI management continued to refer to several opportunities in the CDMO segment – Some already starte...
Sell Divi's Laboratories Ltd. For Target Rs. 3017 By Elara Securities India
Sell Divi's Laboratories Ltd. For Target Rs. 3017 By Elara Securities India
Source: Elara Capital
2024-03-26 02:03:26 pm
Add Divi`s Labs Ltd for Target Rs. 4,077 - Choice Broking Ltd Divi's Laboratories' quarterly earnings fell below our projections across all metrics. The reported revenue of INR 18.bn indicated an 8.6% YoY growth but a 2.8% QoQ degrowth, the YoY growth was influenced by market dynamics. The constant currency growth stood at 7%. EBITDA increased to INR 4.8bn, reflecting a 19.8% YoY growth and a 2.1% QoQ increase, with the EBITDA margin reaching 26.4%. This margin expansion of 245bps YoY and 127bps QoQ was driven by a slight decline in raw material...
Add Divi`s Labs Ltd for Target Rs. 4,077 - Choice Broking Ltd
Add Divi`s Labs Ltd for Target Rs. 4,077 - Choice Broking Ltd
Source: Choice Broking
2024-02-14 04:42:17 pm
Reduce Divi's Laboratories Ltd For Target Rs.3150 - Prabhudas Lilladher Pvt. Ltd We reduce our FY25E/FY26E EPS estimates by ~10%. Divi’s Laboratories (DIVI) Q3FY24 EBITDA was 11% below our estimate led by lower margins and generic API sales. GMs improved led by better product mix however OPM are still below pre COVID levels. Mgmt. suggested that moderation of raw material prices with commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. However, recovery will be gradual and near-term growth is likely to remain muted. We e...
Reduce Divi's Laboratories Ltd For Target Rs.3150 - Prabhudas Lilladher Pvt. Ltd
Reduce Divi's Laboratories Ltd For Target Rs.3150 - Prabhudas Lilladher Pvt. Ltd
Source: PR Agency
2024-02-13 12:51:58 pm
Divi`s Laboratories surges on reporting 17% rise in Q3 consolidated net profit Divi's Laboratories is currently trading at Rs. 3751.95, up by 100.95 points or 2.76% from its previous closing of Rs. 3651.00 on the BSE. The scrip opened at Rs. 3650.00 and has touched a high and low of Rs. 3822.70 and Rs. 3648.70 respectively. So far 25265 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 4072.35 on 04-Jan-2024 and a 52 week low of Rs. 2730.00 on 14-Mar-2023. Last one week high and low of t...
Divi`s Laboratories surges on reporting 17% rise in Q3 consolidated net profit
Divi`s Laboratories surges on reporting 17% rise in Q3 consolidated net profit
Source: Accord Fintech
2024-02-12 02:24:38 pm
Neutral Divi`s Laboratories Ltd For Target Rs.3,440 - Motilal Oswal Financial Services Ltd Custom synthesis drives earnings Work in progress to enhance peptide opportunity * Divi’s Lab (DIVI) delivered lower-than-estimated earnings in 3QFY24. Its custom synthesis (CS) business has witnessed revival during the quarter, aided by two major contracts with innovator. However, its API business continues to be impacted by reduced pricing. The pricing effect was marginally offset by higher volume off-take. * We cut our estimates by 7%/4%/4% for FY24/FY25/FY26, factoring in a...
Neutral Divi`s Laboratories Ltd For Target Rs.3,440 - Motilal Oswal Financial Services Ltd
Neutral Divi`s Laboratories Ltd For Target Rs.3,440 - Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
2024-02-12 12:17:40 pm
Divi`s Lab posts 17% rise in Q3 net profit to Rs 358 crore Pharma major Divi's Laboratories on Saturday reported a 17 per cent increase in its consolidated net profit to Rs 358 crore for the October-December quarter of the current financial year compared to the corresponding figure of Rs 306 crore in the same period of the previous year. The company’s total revenue for the third quarter was 8.6 per cent higher at Rs 1,855 crore compared to the same period last year. The pharma firm’s earnings before interest, taxes, depreciation...
Divi`s Lab posts 17% rise in Q3 net profit to Rs 358 crore
Divi`s Lab posts 17% rise in Q3 net profit to Rs 358 crore
Source: IANS
2024-02-10 04:54:23 pm
Neutral Divi`s Laboratories Ltd For Target Rs.3,330 - Motilal Oswal Financial Services Ltd Pricing pressure in API segment hurts profitability CS segment sales to pick up pace in the coming quarters * Divis Lab (DIVI) delivered a miss on 2QYF24 earnings. While revenue was in line with estimates, profitability was lower than expectation, partly due to lower pricing in the generic API segment. * We reduce our earnings estimate by 5%/3% for FY24/FY25, factoring in a) increased competition in the API segment, and b) higher tax rate, partly offset by improved growth momentum in...
Neutral Divi`s Laboratories Ltd For Target Rs.3,330 - Motilal Oswal Financial Services Ltd
Neutral Divi`s Laboratories Ltd For Target Rs.3,330 - Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
2023-12-13 12:32:30 pm
Divi's Laboratories shines despite reporting 29% fall in Q2 consolidated net profit Divi's Laboratories is currently trading at Rs. 3514.80, up by 164.90 points or 4.92% from its previous closing of Rs. 3349.90 on the BSE. The scrip opened at Rs. 3350.10 and has touched a high and low of Rs. 3528.20 and Rs. 3300.00 respectively. So far 22192 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 3949.00 on 08-Aug-2023 and a 52 week low of Rs. 2730.00 on 14-Mar-2023. Last one week high and low of t...
Divi's Laboratories shines despite reporting 29% fall in Q2 consolidated net profit
Divi's Laboratories shines despite reporting 29% fall in Q2 consolidated net profit
Source: Accord Fintech
2023-11-06 03:55:20 pm